Jerini’s Firazyr For HAE Gets Advisory Committee Review Feb. 20
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pulmonary-Allergy Drugs Advisory Committee is slated to review icatibant for hereditary angioedema.
You may also be interested in...
Shire Finally Able To Move Firazyr Forward
Shire reports positive phase III results for its HAE drug and may file a complete response in the next few months.
Shire Finally Able To Move Firazyr Forward
Shire reports positive phase III results for its HAE drug and may file a complete response in the next few months.
Jerini To Submit Complete Response Letter
With five companies in a race to control the HAE therapeutic space, three announce progress.